BioVaxys Technology Corp (OTCQB: $BVAXF ; CSE: $BIOV ; Frankfurt: 5LB) is a clinical-stage immunotherapy company developing cancer vaccines and next-generation delivery platforms across oncology, infectious disease, and animal health. The company currently sits at a market cap under $10 million even after executing one of the more monumental acquisitions  in recent biotech history: In February 2024, BVAXF paid $750,000 cash plus shares for a patent portfolio and clinical pipe